Dr. West Discusses Anticipated Future Clinical Trials

H. Jack West, MD
Published: Monday, Aug 01, 2011



H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, explains his anticipation to see an overall survival benefit emerge from the PARAMOUNT study examining continuation maintenance with pemetrexed in non-small cell lung cancer. He mentions a strong interest in clinical trials examining next generation studies such as crizotinib in patients that do not have the ALK rearrangement and BRAF targeted therapies which are still in their infancy.


H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, explains his anticipation to see an overall survival benefit emerge from the PARAMOUNT study examining continuation maintenance with pemetrexed in non-small cell lung cancer. He mentions a strong interest in clinical trials examining next generation studies such as crizotinib in patients that do not have the ALK rearrangement and BRAF targeted therapies which are still in their infancy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x